Fig. 1From: Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progressionPlasma NfL and p-tau181 levels in the cohort. Boxplots of plasma NfL (a) and p-tau181 (b) concentrations in cognitively healthy participants (CN) and patients with cognitive impairment (CI). Both groups were further stratified according to AD CSF biomarker profile. Mean concentrations between pairs of groups were compared using T-tests. *, p-value < 0.05; ***, p-value < 0.001Back to article page